Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhen you start Wegovy, the first few weeks look nothing like the rest of your treatment — and that surprises a lot of people. The honest answer is this: early on, your body is adjusting to semaglutide, not yet delivering peak results. Nausea is common, appetite changes are uneven, and weight loss in week one is usually modest. That is entirely normal, and it does not mean the treatment is not working. Wegovy is a once-weekly injectable semaglutide licensed in the UK for weight management in adults — it is a prescription-only medicine, so a prescriber assesses whether it is right for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common misunderstanding people bring to their first pen is that Wegovy kicks in immediately. It does not, and that is by design. The starting dose exists specifically to reduce the chance of nausea and other gastrointestinal effects, it is the body's introduction to semaglutide, not the dose at which the medicine is doing its full therapeutic work. Expecting dramatic weight loss in the first two weeks sets people up for unnecessary disappointment, and sometimes causes them to stop treatment too early.
What actually happens at 0.25 mg is a gradual adjustment. Appetite may shift a little. Some people notice they feel full sooner at meals. Others notice almost nothing except mild queasiness after injection day. Both experiences are normal. The first week on Wegovy is largely about settling your system, and the pace of change tends to pick up as the dose titration progresses.
The STEP 1 trial, published in the New England Journal of Medicine, followed adults on 2.4 mg semaglutide for 68 weeks alongside lifestyle intervention and reported an average body-weight reduction of around 15%. That figure was not achieved in a fortnight, it built steadily across the full course of treatment. If you want a clear picture of what to expect when you start Wegovy, understanding that trajectory makes the early weeks much easier to navigate.
Gastrointestinal effects are the most frequently reported experience when starting semaglutide. Nausea tops the list, followed by constipation, diarrhoea, indigestion and occasional burping or reflux. Headaches and fatigue appear in a smaller number of people. Injection-site redness or mild soreness is possible but usually brief.
The pattern for most people is that these effects are noticeable in the day or two after the first few injections, then gradually ease as the weeks go on. Eating smaller meals, staying well hydrated and avoiding rich or fatty food around injection day all help. If you find early side effects difficult, talking to your prescriber before the next dose step is worth doing, titration can be slowed where clinically appropriate.
Serious reactions are uncommon but should not be ignored. Severe stomach pain that spreads to the back, with or without vomiting, can be a sign of pancreatitis and needs urgent medical attention. The MHRA Yellow Card scheme is there for reporting any suspected side effect, patients can use it directly, and doing so helps inform national safety monitoring. If you are unsure whether a symptom needs attention, contact your prescriber or 111 rather than waiting.
The standard dose pathway moves from 0.25 mg through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose, with roughly four weeks at each step. Each increase can bring a brief return of mild nausea, the pattern often repeats in a smaller form at each new rung. Most people find it noticeably milder than the first time.
Appetite suppression tends to become more consistent as the dose climbs. Many people describe a shift in how food feels, cravings become quieter, portion sizes naturally reduce, and the internal noise around eating settles. This is semaglutide slowing gastric emptying and acting on appetite-regulating pathways in the brain. Our guide covering Wegovy, what to expect across the full course has more detail on realistic timelines by dose step, including how the picture changes as the dose climbs.
Weight loss across the titration period is rarely linear. Some weeks the scale barely moves; others it shifts more noticeably. That is not a sign of failure, it reflects normal biology, hydration changes and the body's metabolic responses. Staying consistent with the injection schedule and maintaining lifestyle changes matters more than any single week's number. If you want a fuller sense of what taking Wegovy involves across the whole journey, including how appetite and side effects typically shift at each stage, that guide walks through the experience in practical terms. If you want to explore how others describe the experience by specific week, week five is a useful reference point, it is often where appetite suppression becomes more consistent for many people.
Wegovy is injected once a week, on the same day each week. You can choose the day that fits your routine, some people pick a day when they are at home in the afternoon rather than the morning before work, since tiredness occasionally follows the first few injections. The pen goes into the abdomen, thigh or upper arm; rotating the site prevents localised irritation. Storage is in the fridge at 2–8°C, so it sits alongside other refrigerated items, just treat it carefully and keep the cap on until you are ready. For precise storage windows away from refrigeration, always follow the instructions in the Patient Information Leaflet that comes with the pen.
If you are on oral contraceptives, NHS England's guidance on weight-management injections notes that semaglutide does not appear to reduce pill absorption in the same way tirzepatide does, but your prescriber will discuss contraception as part of your consultation. Women who are pregnant, breastfeeding or trying to conceive should not use Wegovy, and the medicine should be stopped before attempting to conceive, in line with your prescriber's advice.
Treatment cost is one of the practical questions people search early. If you are thinking about what private Wegovy treatment involves financially, our overview of weight-loss treatment options sets out what is included in a legitimate private prescription service and what to watch for when comparing providers. Starting treatment through a regulated pharmacy means a prescriber reviews your information before anything is dispensed, that clinical step is not optional, and it is not a formality.
If you are ready to talk through whether Wegovy suits your situation, start your free consultation with our prescribers. A real clinician reads your answers the same day, not a script, not a system.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.